help button home button Endocrine Society JCEM JCEM Call for Nominations for EIC
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a related Letter to the Editor
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Copyright Permission
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Schteingart, D. E.
Right arrow Articles by Strieter, R. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schteingart, D. E.
Right arrow Articles by Strieter, R. M.
Right arrowPubmed/NCBI databases
*Compound via MeSH
*Substance via MeSH
Hazardous Substances DB
*HYDROCORTISONE
The Journal of Clinical Endocrinology & Metabolism Vol. 86, No. 8 3968-3974
Copyright © 2001 by The Endocrine Society


Other Original Articles

Overexpression of CXC Chemokines by an Adrenocortical Carcinoma: A Novel Clinical Syndrome

David E. Schteingart, Thomas J. Giordano, Ricardo S. Benitez, Marie D. Burdick, Monica N. Starkman, Douglas A. Arenberg and Robert M. Strieter

Departments of Internal Medicine (D.E.S., R.S.B., D.A.A.), Pathology (T.J.G.), and Psychiatry (M.N.S.), University of Michigan Medical School, Ann Arbor, Michigan 48109; and Department of Medicine (M.D.B., R.M.S.), Division of Pulmonary and Critical Medicine, UCLA School of Medicine, Los Angeles, California 90024

Address all correspondence and requests for reprints to: David E. Schteingart. M.D., University of Michigan Medical Center, 5570 MSRB II, Box 0678, 1150 West Medical Center Drive, Ann Arbor, Michigan 48109-0001. E-mail: dschtein{at}umich.edu

Abstract

A patient with adrenocortical carcinoma presented with fever, leukocytosis, and increased acute phase reactants. The tumor was infiltrated with neutrophils. Immunohistochemical staining of the tumor showed positive signal for epithelial neutrophil-activating protein-78, an angiogenic and chemotactic CXC chemokine. Conditioned medium from tumor-derived cells (RL-251) showed high concentration of IL-8, epithelial neutrophil-activating protein-78, Gro {alpha}, and Gro {gamma}, angiogenic CXC chemokines with a potential role in tumorigenesis. An adrenal cancer/severe combined immunodeficiency mouse chimera was developed. Mice grew tumors rapidly, and circulating levels of IL-8 and epithelial neutrophil-activating protein-78 were detected. In contrast, animals transplanted with NCI-H295 cells, a nonchemokine-secreting cell line, grew tumors more slowly and did not have detectable chemokine levels. Similar to the patient, mice with RL-251 tumors developed marked leukocytosis and neutrophilia, and their tumors were infiltrated with neutrophils. Mice were passively immunized with epithelial neutrophil-activating protein-78 antisera. A marked decrease in tumor growth was observed. Potential for chemokine production by other adrenocortical tumors was investigated by RT-PCR in archival material. Six of seven adrenal carcinomas and one of three adenomas had cDNA for IL-8; six of seven carcinomas and the three adenomas had cDNA for epithelial neutrophil-activating protein-78. We concluded that the clinical presentation of this case resulted from increased tumor production of chemotactic chemokines. Through their angiogenic and chemotactic properties these chemokines may play an important role in adrenal tumorigenesis.




This article has been cited by other articles:


Home page
J. Clin. Endocrinol. Metab.Home page
T. Else, T. J. Giordano, and G. D. Hammer
Evaluation of Telomere Length Maintenance Mechanisms in Adrenocortical Carcinoma
J. Clin. Endocrinol. Metab., April 1, 2008; 93(4): 1442 - 1449.
[Abstract] [Full Text] [PDF]


Home page
Clin. Cancer Res.Home page
Y. Wen, S. F. Giardina, D. Hamming, J. Greenman, E. Zachariah, M. D. Bacolod, H. Liu, J. Shia, P. S. Amenta, F. Barany, et al.
GRO{alpha} Is Highly Expressed in Adenocarcinoma of the Colon and Down-Regulates Fibulin-1.
Clin. Cancer Res., October 15, 2006; 12(20): 5951 - 5959.
[Abstract] [Full Text] [PDF]


Home page
EndocrinologyHome page
D. G. Romero, G. R. Vergara, Z. Zhu, G. S. Covington, M. W. Plonczynski, L. L. Yanes, E. P. Gomez-Sanchez, and C. E. Gomez-Sanchez
Interleukin-8 Synthesis, Regulation, and Steroidogenic Role in H295R Human Adrenocortical Cells
Endocrinology, February 1, 2006; 147(2): 891 - 898.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
M. Rotondi, A. Falorni, A. De Bellis, S. Laureti, P. Ferruzzi, P. Romagnani, A. Buonamano, E. Lazzeri, C. Crescioli, M. Mannelli, et al.
Elevated Serum Interferon-{gamma}-Inducible Chemokine-10/CXC Chemokine Ligand-10 in Autoimmune Primary Adrenal Insufficiency and in Vitro Expression in Human Adrenal Cells Primary Cultures after Stimulation with Proinflammatory Cytokines
J. Clin. Endocrinol. Metab., April 1, 2005; 90(4): 2357 - 2363.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
S. R. Bornstein and P. J. Hornsby
What Can We Learn from Gene Expression Profiling for Adrenal Tumor Management?
J. Clin. Endocrinol. Metab., March 1, 2005; 90(3): 1900 - 1902.
[Full Text] [PDF]


Home page
Ann. N. Y. Acad. Sci.Home page
L. S. KIRSCHNER
Signaling Pathways in Adrenocortical Cancer
Ann. N.Y. Acad. Sci., June 1, 2002; 968(1): 222 - 239.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Endocrinology Endocrine Reviews J. Clin. End. & Metab.
Molecular Endocrinology Recent Prog. Horm. Res. All Endocrine Journals
Copyright © 2001 by The Endocrine Society